FIL Ltd Invests $1.06 Million in Glaukos Co. (NYSE:GKOS)

FIL Ltd purchased a new position in Glaukos Co. (NYSE:GKOS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 7,089 shares of the medical instruments supplier's stock, valued at approximately $1,063,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Glaukos by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 5,974,971 shares of the medical instruments supplier's stock valued at $895,887,000 after purchasing an additional 101,838 shares during the last quarter. Invesco Ltd. grew its holdings in Glaukos by 4.9% during the 4th quarter. Invesco Ltd. now owns 1,458,635 shares of the medical instruments supplier's stock valued at $218,708,000 after buying an additional 68,310 shares in the last quarter. Geode Capital Management LLC increased its position in Glaukos by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 1,197,215 shares of the medical instruments supplier's stock worth $179,555,000 after purchasing an additional 25,199 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of Glaukos by 1,235.4% during the 4th quarter. Alliancebernstein L.P. now owns 816,153 shares of the medical instruments supplier's stock valued at $122,374,000 after buying an additional 755,035 shares in the last quarter. Finally, William Blair Investment Management LLC bought a new stake in shares of Glaukos in the 4th quarter valued at approximately $121,390,000. Institutional investors own 99.04% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Needham & Company LLC boosted their price objective on shares of Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Piper Sandler cut their price objective on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a research report on Tuesday. Wells Fargo & Company increased their price target on Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Mizuho dropped their price objective on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday. Finally, Truist Financial dropped their price objective on shares of Glaukos from $185.00 to $140.00 and set a "buy" rating on the stock in a report on Friday, April 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $156.17.

Insiders Place Their Bets

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Tomas Navratil sold 3,416 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares in the company, valued at $10,658,380.18. The trade was a 4.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Glaukos Trading Down 6.0 %

NYSE GKOS traded down $5.70 on Wednesday, hitting $88.82. 1,691,577 shares of the company were exchanged, compared to its average volume of 636,467. Glaukos Co. has a twelve month low of $77.91 and a twelve month high of $163.71. The company's 50 day moving average price is $110.40 and its 200-day moving average price is $131.88. The firm has a market capitalization of $5.02 billion, a P/E ratio of -30.95 and a beta of 0.88. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Analysts predict that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.